DelveInsight’s, “Ischemic Stroke Pipeline Insight 2023” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Ischemic Stroke pipeline landscape. It covers the Ischemic Stroke pipeline drug profiles, including Ischemic Stroke clinical trials and nonclinical stage products. It also covers the Ischemic Stroke therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Recent Developmental Activities in the Ischemic Stroke Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Ischemic Stroke Pipeline Landscape @ Ischemic Stroke Pipeline Outlook
Ischemic Stroke Overview
Stroke is a leading cause of death and disability worldwide and can be broadly classified into ischaemic stroke and haemorrhagic stroke, the latter of which includes intracerebral haemorrhage and subarachnoid haemorrhage. Ischaemic stroke is defined as infarction of the brain, spinal cord or retina1 and represents ~71% of all strokes globally.
Key Takeaways from the Ischemic Stroke Pipeline Report
Find out more about the Ischemic Stroke Diagnosis and Treatment of patients @ Ischemic Stroke Ongoing Clinical Trials Analysis
Ischemic Stroke Emerging Drugs Profile
3K3A-APC, is a genetically engineered variant of human activated protein C (APC), a serine protease optimized for human therapeutic use. 3K3A-APC was designed to enhance the cytoprotective and anti-inflammatory activities of APC while greatly reducing its anti-coagulant activity. APC is a protease possessing two distinct functions: 1) anticoagulant properties mediated by proteolysis of coagulation factors Va and VIIIa, and 2) cytoprotective effects including anti-apoptotic effects, anti-inflammatory effects, and endothelial barrier stabilization. ZZ Biotech has completed RHAPSODY, a multicenter Phase II clinical trial of its experimental drug, 3K3A-APC and is in Phase III for the treatment of patients suffering from acute ischemic stroke. This study was supported by the National Institutes of Health through a pair of NeuroNEXT grants.
BMS-986177 (Factor XIa) is an investigational anticoagulant compound. Factor XIa (FXIa) plays a key role in the activation and amplification of the coagulation cascade via the intrinsic pathway. A small study of Hemophilia C patients showed a lower risk of stroke. Currently the product is in Phase III stage of development for treatment of Ischemic Stroke and Transient Ischemic Attack (TIA).
XY03 EA, is an investigational drug being developed by Shijiazhuang Yiling Pharmaceutical Co. Ltd. XY03-EA decreased the cerebral injuries and NDS by increasing cerebral blood flow, improving brain energy metabolism, accelerating ROS clearance, suppressing inflammatory responses, and inhibiting autophagy in the MCAO/R model rats. In the nonhuman primate MCAO/R model, the treatment of XY03-EA for 3 weeks could significantly inhibit the NDS progression rate and indicate a positive trend to reduce the infarct volume in a dose-dependent way. Mechanistically, XY03-EA inhibited ROS-dependent autophagy activation and thereby protected the PC-12 cells from the autophagic cell death induced by OGD/R. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Acute Ischemic Stroke.
NoNO-42 is a nerinetide analog intended for use in people experiencing an acute ischemic stroke with or without thrombolytics. Of the 650,000 people experiencing an acute ischemic stroke treated annually in US hospitals, approximately 10% receive a thrombolytic, which may reduce the applicability of nerinetide. Compatibility of NoNO-42 with thrombolytics broadens the availability neuroprotection and neurorestoration to all hospital treated strokes. Currently, the drug is in Phase I stage of its development for the treatment of acute ischemic stroke.
Ischemic Stroke Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Ischemic Stroke. The companies which have their Ischemic Stroke drug candidates in the most advanced stage, i.e. phase III include, ZZ Biotech.
Discover more about the list of Ischemic Stroke FDA-approved drugs @ Ischemic Stroke Treatment Landscape
Scope of the Ischemic Stroke Pipeline Report
Dive deep into rich insights for Ischemic Stroke Emerging Therapies and Ongoing Clinical Trials; visit @ Ischemic Stroke Emerging Therapies and Companies
Table of Content
For further information on the Ischemic Stroke Pipeline therapeutics, reach out to Ischemic Stroke Market Drivers and Barriers
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/